Article Text
Unexpected outcome (positive or negative) including adverse drug reactions
Case report
Linagliptin-associated bullous pemphigoid treated with rituximab
Abstract
Dipeptidyl peptidase 4 (DPP-4) inhibitors are increasingly used these days in management of diabetes. There has been reported in a few case reports of increasing association between DPP-4 inhibitor use and bullous pemphigoid (BP). We report a case of association between linagliptin use and BP and subsequent treatment with rituximab.
- contraindications and precautions
- drug interactions
- endocrine system
- dermatology